Dr. Denmeade is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
201 North Broadway Street
Viragh BLDG 5th FL
Baltimore, MD 21287Phone+1 410-955-8964Fax+1 410-367-2194
Summary
- Dr. Samuel Denmeade is the R. Dale Hughes Professor of Oncology and Director of the Genitourinary Oncology Program at Johns Hopkins in Baltimore, MD. He is affiliated with multiple hospitals in the area, including Johns Hopkins Hospital and Johns Hopkins Bayview Medical Center. He received his medical degree from Columbia University Vagelos College of Physicians and Surgeons and has been in practice 28 years. He is experienced in treatment of advanced prostate cancer. He has more than 200 publications and developed the concept of Bipolar Androgen Therapy for metastatic prostate cancer
Education & Training
- Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1993 - 1996
- University of ChicagoResidency, Internal Medicine, 1989 - 1992
- Columbia University Vagelos College of Physicians and SurgeonsClass of 1989
Certifications & Licensure
- MD State Medical License 1993 - 2026
- VA State Medical License 2024 - 2026
- PA State Medical License 1992 - 2024
- NC State Medical License 2020 - 2022
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
- Top Doctors:Baltimore Area Castle Connolly, 2012
- Top Doctors:Washington-Baltimore Castle Connolly, 2012
Clinical Trials
- A Pilot Study of Parenteral Testosterone and Oral Etoposide as Therapy for Men With Castration Resistant Prostate Cancer Start of enrollment: 2010 Mar 01
- Bipolar Androgen-based Therapy for Prostate Cancer (BAT) Start of enrollment: 2013 Jan 01
- Allogeneic Human Bone Marrow Derived Mesenchymal Stem Cells in Localized Prostate Cancer Start of enrollment: 2013 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- 32 citationsLack of an effect of high dose isoflavones in men with prostate cancer undergoing androgen deprivation therapy.Preetika Sharma, Amy B. Wisniewski, Milena Braga-Basaria, Xiaoqiang Xu, Mary Yep
The Journal of Urology. 2009-11-01 - 35 citationsComparative study of PSMA expression in the prostate of mouse, dog, monkey, and human.Saurabh Aggarwal, Rebecca M. Ricklis, Simon A. Williams, Samuel R. Denmeade
The Prostate. 2006-06-15 - 653 citationsOutcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical TrialRyan Phillips, William Shi, Matthew P. Deek, Noura Radwan, Su Jin Lim
JAMA Oncology. 2020-05-01
Journal Articles
- Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate CancerEmmanuel S Antonarakis, Ashley E Ross, Michael A Gorin, Samuel R Denmeade, Channing J Paller, Kenneth J Pienta, Mario A Eisenberger, JAMA Oncology
Press Mentions
- Prostate Cancer Drug Is Found to Be an Effective Antiviral Against Coronavirus and the Common ColdFebruary 3rd, 2021
- Health Tips: This Experimental Prostate Cancer Treatment Is Shrinking TumorsApril 29th, 2017
- Health Tips This Experimental Prostate Cancer Treatment Is Shrinking TumorsApril 28th, 2017
- Join now to see all
Other Languages
- Spanish
External Links
- Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/samuel-denmeade
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: